About me
Harry Yuna, PhD, MBA, is the Global CI Lead of the Hematologic Oncology franchise at Takeda Oncology. His expertise covers broad disease areas including myeloproliferative neoplasms, lymphomas, leukemia, and multiple myeloma etc. As the CI Lead, he is responsible for intelligence collection, insight generation, and customer engagement to drive tactics and strategy development of multiple inline and pipeline assets. He has led the effort to innovate CI search and analysis with the development of an AI-empowered CI platform, which has transformed the CI insights generation and improved access in the organization. Prior to Takeda, he spent over a decade at Novo Nordisk leading market and competitor monitoring efforts across diabetes, MASH and obesity markets. He started the Obesity CI Program before the launch of Saxenda and grew it to a full-blown, industry leading intelligence program. Harry holds an MBA degree from Duke University and a Biochemistry PhD from the Chinese Academy of Sciences. He is a strong advocate for transforming the CI practice through innovation, insight integration, and customer engagement.
